An error in a Phase IIb trial for Cytokinetics' (CYTK) Tirasemtiv treatment for Lou Gehrig's...

|By:, SA News Editor

An error in a Phase IIb trial for Cytokinetics' (CYTK) Tirasemtiv treatment for Lou Gehrig's disease caused 58 patients who initially received the drug to later receive a placebo. So far 50 patients have been enrolled in the trial. Cytokinetics now has to decide whether to raise the number of patients in the study, which could increase its costs and delay the results. Shares are about to resume trading after being halted.